FOSUN PHARMA: The controlling subsidiary FOSUN PHARMA Industry signed a "Cooperation and Option Agreement" with partner ClavisBio, which can receive up to $363 million in payments

On December 18th, the company's controlling subsidiary FOSUN PHARMA signed a "Cooperation and Option Agreement" with partner ClavisBio. According to the agreement, during the specified cooperation period, FOSUN PHARMA and ClavisBio will jointly select targets (based on nominations from Clavis Bio) and advance the preclinical development of compounds targeting the selected targets (i.e., the cooperation project). Clavis Bio has the exclusive option for global development, production, and commercialization of these cooperation projects, except within mainland China, Hong Kong, and Macau; regardless of whether the partner exercises the above option, the Group retains exclusive rights for development, production, and commercialization of these cooperation projects within mainland China, Hong Kong, and Macau